AlphaStocks
5.1
Consider Buy

Astrana Health, Inc. (ASTH)

As of Sep 19, 2026, Astrana Health, Inc. (ASTH) scores 5.1/10 on AlphaStocks' five-model composite, #104 of 168 Health Care stocks. At $34, ASTH trades 72% above its model fair value of $20.

Health Care / Health Care Facilities

S&P SmallCap 600

$34.32

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 19, 2026

#104out of 168 in Health Care

Is Astrana Health, Inc. a Good Investment in 2026?

Astrana Health, Inc. (ASTH) scores 5.1 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates Astrana Health, Inc. as Attractive (Earnings yield 5.3% · ROC 51%). However, the Lynch model rates it Caution — High PEG — growth premium · Slow Grower. Astrana Health, Inc. currently trades 72% above its estimated fair value of $20. Astrana Health, Inc. ranks #104 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E62.5ROE3.5Market Cap2B

Estimated Fair Value

$19.9572% above

Trading above estimated fair value. P/e of 63x implies high growth expectations. eps growth of -47% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

3/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Caution

High PEG — growth premium · Slow Grower

Greenblatt

Attractive

Earnings yield 5.3% · ROC 51%

Frequently Asked Questions

Is Astrana Health, Inc. (ASTH) a good investment?
As of Sep 19, 2026, Astrana Health, Inc. (ASTH) scores 5.1/10 on AlphaStocks' five-model composite, #104 of 168 Health Care stocks. At $34, ASTH trades 72% above its model fair value of $20. That score is below average, suggesting caution.
What is Astrana Health, Inc.'s Piotroski F-Score?
Astrana Health, Inc.'s Piotroski F-Score status is Neutral. The raw score is 3/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ASTH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $20, ASTH appears overvalued. The stock currently trades 72% above its estimated fair value. Trading above estimated fair value. P/e of 63x implies high growth expectations. eps growth of -47% may not justify the premium.
How does ASTH compare to other Health Care stocks?
Astrana Health, Inc. ranks #104 out of 168 stocks in the Health Care sector, placing it in the top 62% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ASTH?
AlphaStocks evaluates ASTH using five proven investment models. Piotroski: Neutral; Buffett: Caution; Graham: Caution; Lynch: Caution; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 5.1/10.

Similar Stocks

THCEHCNHC

Compare ASTH with

ASTH vs THCASTH vs EHCASTH vs NHCASTH vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer